Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01692184 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT01692184 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 54 participants.
The verdict
NCT01692184, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is a 2-part study. The first part is to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of AVL-292 following multiple oral doses; and the second part is to evaluate the effect of food on the pharmacokinetics of a single oral dose of AVL-292.
Interventions
- DRUG Placebo capsules
- DRUG 50 mg AVL-292
- DRUG 100 mg AVL-292
- DRUG 200 mg AVL-292
- DRUG 350 mg AVL-292
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2012-08-01 |
| Est. Completion | 2012-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01692184
The ClinicalTrials.gov registry entry for NCT01692184 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo capsules is the first listed.
NCT01692184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01692184 about?
NCT01692184 is a clinical study titled "Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292". This is a 2-part study. The first part is to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of AVL-292 following multiple oral doses; and the second part is to evaluate the effect of food on the pharmacokinetics of a single oral dose of AVL-292.
What is the current status of trial NCT01692184?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2012-08-01. Estimated completion is 2012-10-08.
What interventions are being tested in trial NCT01692184?
The interventions under investigation include: Placebo capsules (DRUG), 50 mg AVL-292 (DRUG), 100 mg AVL-292 (DRUG), 200 mg AVL-292 (DRUG), 350 mg AVL-292 (DRUG).
Who is sponsoring clinical trial NCT01692184?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.